Minsheng Health announced that the company has received the Drug Supplementary Application Approval Notice for Glucosamine Sulfate Capsules issued by the National Medical Products Administration. The drug is indicated for primary and secondary osteoarthritis. The company stated that obtaining this drug approval will help enrich its product portfolio and enhance market competitiveness. The company also cautioned that pharmaceutical sales are susceptible to industry policy changes, market competition, and other factors, and therefore involve uncertainty.
Hangzhou Minsheng Healthcare Co LtdMinsheng Health received NMPA drug supplementary application approval for Glucosamine Sulfate Capsules, enriching its product portfolio and competitiveness.
